The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant… The post The FDA Is Trying To Make Corporate Free Speech Situational appeared on BitcoinEthereumNews.com. BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images) Getty Images While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future. Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit. The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music. Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant…

The FDA Is Trying To Make Corporate Free Speech Situational

For feedback or concerns regarding this content, please contact us at [email protected]

BENSENVILLE, ILLINOIS – SEPTEMBER 10: Flanked by U.S. Attorney General Pam Bondi (rear), and FDA Commissioner Marty Makary (R), Secretary of Health and Human Services Robert F. Kennedy Jr. speaks to the press outside Midwest Distribution after it was raided by federal agents on September 10, 2025 in Bensenville, Illinois. According to the company, various e-liquids were seized in the raid. (Photo by Scott Olson/Getty Images)

Getty Images

While running for President in 2008, Barack Obama famously chanted “Yes we can.” Love or hate his political views, Obama’s politics were quite effective. He was asking voters to think big, to envision a much better future.

Advertisers no doubt approved. That’s because ads routinely evoke things not as they are, but as they could be. Gyms and exercise equipment companies don’t promote their locations and equipment with flabby, lumbering people, rather their ads show fit, upright, energetic individuals. A look ahead. Restaurants do the same with ads showing happy people enjoying impressively put together plates of food. Conversely, ads meant to convince smokers to quit have not infrequently shown the worst of the worst future downsides of the habit.

The nature of advertising comes to mind as FDA commissioner Marty Makary puzzlingly brags that “The Trump Administration Is Taking On Big Pharma” in the New York Times. Makary laments pharmaceutical ads that “are filled with dancing patients, glowing smiles and catch jingles that drown out the fine print.” Not explained is whether Makary would be happier if drug companies placed ads with immobile patients, frowns, and funereal music.

Seriously, what does he expect? Does he want drug companies to commit billions to drug development to accompany their achievements with imagery defined by misery? Has Makary stopped to contemplate the myriad shareholders lawsuits drugmakers would face if, upon risking staggering sums meant to create a healthier future, they made sure to downplay or outright deny their achievements?

Makary pats his FDA and Trump administration on the back for acting to “rein in misleading pharmaceutical ads,” but it’s the equivalent of the Trump administration demanding that pharmaceutical companies demean their capabilities. How could the allegedly pro-business Trump administration make such a demand, one that no other politician or business would ever be expected to abide?

To which Makary and his defenders might reply that with pharmaceutical drugs, the rules should be different. Since health and health outcomes are on the line, sometimes of the life and death variety, pharmaceutical companies must follow a different set of rules. Except that pharmaceutical companies already do. And Makary knows this truth well.

As evidenced by the years of work and billions spent just to attain drug approval, pharmaceutical companies go to enormous lengths to get their innovations into the marketplace. Their drugs are FDA approved. Which is the point, or should be.

In seeking greater policing of drug advertising, Makary is adding another layer to the already substantial oversight provided by the FDA, oversight that has yet more layers. While pharmaceutical companies can advertise their FDA approved drugs, would-be patients can still only attain them insofar as they’re prescribed by a doctor. Which of course answers Makary’s odd critique that drugmakers are targeting potential users with “misleading ads.” Really? How?

Lest Makary forget, the ads are yet again for FDA approved drugs that are once again only accessible with a doctor-signed prescription. Which raises a basic question: if the FDA is doing its job in the approval process, and doctors are doing their jobs, why the limits on the free speech rights of pharmaceutical companies to advertise the health possibilities that come with their innovations? Why indeed.

Absent a compelling answer from Makary, it’s difficult to find a compelling reason for the Trump administration to make free speech situational. Pharmaceutical companies prosper by improving our lives. Let them advertise their capacity to do just that.

Source: https://www.forbes.com/sites/johntamny/2025/09/17/the-fda-is-trying-to-make-corporate-free-speech-situational/

Market Opportunity
SynFutures Logo
SynFutures Price(F)
$0.005674
$0.005674$0.005674
+7.54%
USD
SynFutures (F) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Trump Wants Rate Cuts Now — The Iran War and Oil Prices Say Otherwise

Trump Wants Rate Cuts Now — The Iran War and Oil Prices Say Otherwise

TLDR Trump posted on Truth Social demanding Fed Chair Powell cut rates “immediately” rather than wait for next week’s FOMC meeting. Markets have priced out most
Share
Coincentral2026/03/13 15:54
UK GDP arrives at 0% MoM in January vs. 0.2% expected

UK GDP arrives at 0% MoM in January vs. 0.2% expected

The post UK GDP arrives at 0% MoM in January vs. 0.2% expected appeared on BitcoinEthereumNews.com. The UK Gross Domestic Product (GDP) arrived at 0% MoM in January
Share
BitcoinEthereumNews2026/03/13 15:59
Egrag Crypto: XRP Could be Around $6 or $7 by Mid-November Based on this Analysis

Egrag Crypto: XRP Could be Around $6 or $7 by Mid-November Based on this Analysis

Egrag Crypto forecasts XRP reaching $6 to $7 by November. Fractal pattern analysis suggests a significant XRP price surge soon. XRP poised for potential growth based on historical price patterns. The cryptocurrency community is abuzz after renowned analyst Egrag Crypto shared an analysis suggesting that XRP could reach $6 to $7 by mid-November. This prediction is based on the study of a fractal pattern observed in XRP’s past price movements, which the analyst believes is likely to repeat itself in the coming months. According to Egrag Crypto, the analysis hinges on fractal patterns, which are used in technical analysis to identify recurring market behavior. Using the past price charts of XRP, the expert has found a certain fractal that looks similar to the existing market structure. The trend indicates that XRP will soon experience a great increase in price, and the asset will probably reach the $6 or $7 range in mid-November. The chart shared by Egrag Crypto points to a rising trend line with several Fibonacci levels pointing to key support and resistance zones. This technical structure, along with the fractal pattern, is the foundation of the price forecast. As XRP continues to follow the predicted trajectory, the analyst sees a strong possibility of it reaching new highs, especially if the fractal behaves as expected. Also Read: Why XRP Price Remains Stagnant Despite Fed Rate Cut #XRP – A Potential Similar Set-Up! I've been analyzing the yellow fractal from a previous setup and trying to fit it into various formations. Based on the fractal formation analysis, it suggests that by mid-November, #XRP could be around $6 to $7! Fractals can indeed be… pic.twitter.com/HmIlK77Lrr — EGRAG CRYPTO (@egragcrypto) September 18, 2025 Fractal Analysis: The Key to XRP’s Potential Surge Fractals are a popular tool for market analysis, as they can reveal trends and potential price movements by identifying patterns in historical data. Egrag Crypto’s focus on a yellow fractal pattern in XRP’s price charts is central to the current forecast. Having contrasted the market scenario at the current period and how it was at an earlier time, the analyst has indicated that XRP might revert to the same price scenario that occurred at a later cycle in the past. Egrag Crypto’s forecast of $6 to $7 is based not just on the fractal pattern but also on broader market trends and technical indicators. The Fibonacci retracements and extensions will also give more insight into the price levels that are likely to be experienced in the coming few weeks. With mid-November in sight, XRP investors and traders will be keeping a close eye on the market to see if Egrag Crypto’s analysis is true. If the price targets are reached, XRP could experience one of its most significant rallies in recent history. Also Read: Top Investor Issues Advance Warning to XRP Holders – Beware of this Risk The post Egrag Crypto: XRP Could be Around $6 or $7 by Mid-November Based on this Analysis appeared first on 36Crypto.
Share
Coinstats2025/09/18 18:36